Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-08046876 |
| Synonyms | |
| Therapy Description |
PF-08046876 is an antibody-drug conjugate (ADC) comprising an antibody targeting integrin beta-6 (IB6) linked to a camptothecin-class topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1577). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-08046876 | PF 08046876|PF08046876 | PF-08046876 is an antibody-drug conjugate (ADC) comprising an antibody targeting integrin beta-6 (IB6) linked to a camptothecin-class topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1577). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07090499 | Phase I | PF-08046876 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Recruiting | USA | CAN | 1 |